Black and Hispanic Patients are More Likely to be Treated with Disease Modifying Therapies for Multiple Sclerosis than White patients: Medicare Analysis 2014-2016

被引：0
|
作者：
Xu, L. [1 ]
Williams, M. [2 ]
Amezcua, L. [3 ]
Vignos, M. [4 ]
Gamba, J. [4 ]
Puckrein, G. [1 ]
机构：
[1] Natl Minor Qual Forum, Washington, DC USA
[2] Multiple Sclerosis Ctr Atlanta, Atlanta, GA USA
[3] Keck Sch Med, Dept Neurol, Los Angeles, CA USA
[4] Biogen, Cambridge, MA USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2022年 / 28卷 / 1_SUPPL期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P326
引用
收藏
页码：169 / 169
页数：1
相关论文
共 50 条
  • [31] Olfactory Dysfunction in Patients With Relapsing-Remitting Multiple Sclerosis Treated With Disease-Modifying Therapies
    Wnuk, Marcin
    Drabik, Leszek
    Marona, Monika
    Szaleniec, Joanna
    Bryll, Amira
    Karcz, Paulina
    Kolasinska, Justyna
    Kolasinska, Monika
    Ziekiewicz, Maciej
    Skladzien, Jacek
    Popiela, Tadeusz
    Slowik, Agnieszka
    ENT-EAR NOSE & THROAT JOURNAL, 2022, 101 (10) : 640 - 644
  • [32] Determinants of Disparate Disability Accumulation In Black, Hispanic, and White Patients With Multiple Sclerosis
    Michael, C.
    Perez, C.
    Lincoln, J.
    Agyei, P.
    Elsehety, M.
    Singh, S. K.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (1_SUPPL) : 105 - 105
  • [33] Comparison of adherence and persistence among multiple sclerosis patients treated with disease-modifying therapies: a retrospective administrative claims analysis
    Halpern, Rachel
    Agarwal, Sonalee
    Dembek, Carole
    Borton, Leigh
    Lopez-Bresnahan, Maria
    PATIENT PREFERENCE AND ADHERENCE, 2011, 5 : 73 - 84
  • [34] A retrospective claims analysis: Compliance and discontinuation rates among Canadian patients with multiple sclerosis treated with disease-modifying therapies
    Duquette, Pierre
    Yeung, Michael
    Mouallif, Soukaina
    Nakhaipour, Hamid Reza
    Haddad, Paola
    Schecter, Robyn
    PLOS ONE, 2019, 14 (01):
  • [35] Adherence to disease-modifying therapies and attitudes regarding disease in patients with multiple sclerosis
    Ozura, Ana
    Kovac, Lea
    Sega, Sasa
    CLINICAL NEUROLOGY AND NEUROSURGERY, 2013, 115 : S6 - S11
  • [36] Effects of disease-modifying therapies on lipid parameters in patients with multiple sclerosis
    Koca, Nizameddin
    Seferoglu, Meral
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2023, 77
  • [37] Clinical and patient reported outcomes in multiple sclerosis patients on disease modifying therapies
    Fernandes, L.
    Horton, M.
    Russell, M.
    Lily, O.
    Ford, H. L.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 417 - 418
  • [38] The influence of disease-modifying therapies on gut microbiota in patients with multiple sclerosis
    Flaskamp, Martina
    Andlauer, Till
    Uibel, Paula
    Held, Friederike
    Jud, Sarah
    Troci, Alba
    Afzali, Ali
    Gasperi, Christiane
    Giglhuber, Katrin
    Strauss, Eva-Maria
    Berthele, Achim
    Bang, Corinna
    Franke, Andre
    Hemmer, Bernhard
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 328 - 328
  • [39] The influence of disease modifying therapies on immunoglobulin blood levels in patients with multiple sclerosis
    Klein, A. -K.
    Wenzel, M.
    Held, F.
    Muratovic, H.
    Berthele, A.
    Hemmer, B.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 611 - 611
  • [40] Audit of patients switching disease-modifying therapies for the treatment of multiple sclerosis
    Embrey, NH
    Woolmore, JA
    Hawkins, CP
    MULTIPLE SCLEROSIS, 2005, 11 : S159 - S159
12345